Hims & Hers shares rise 6% as peptide compounding policy reaches OMB
Leerink has estimated that compounding the seven reviewed peptides could create a $2.2 billion annual telehealth market, with Hims capturing roughly $440 million.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 15 22:04 ETSource: TradingView
The wire
- 01An OMB posting showed HHS and FDA submitted an interim access policy that, per the Associated Press, would let specialty pharmacies temporarily compound certain unapproved peptides including BPC-157; Hims stock snapped a three-day slump.
- 02Hims bought a California peptide manufacturing plant in early 2025 and CEO Andrew Dudum said validation and stability testing on peptide APIs has begun at its Menlo Park facility.
- 03FDA briefing materials on BPC-157 flagged gaps in clinical evidence, chemical characterization and impurity controls plus possible immune reactions; the July advisory votes were nonbinding and no implementation timetable exists.
From the source
Read at es.tradingview.comHIMS Stock Snaps 3-Day Slump On Peptide Hopes: Trump Administration Reviews Plan That Could Unlock $2.2B Market
Shares of Hims & Hers Health (HIMS) jumped nearly 6% on Thursday, snapping a three-day losing streak as a Trump administration plan to ease restrictions on peptide compounding reached White House review.
